-
Cancer Epidemiology, Biomarkers &... Jul 2023Climate change, the greatest threat to human health of our time, has implications for cancer control efforts throughout the cancer care continuum. The direct and...
Climate change, the greatest threat to human health of our time, has implications for cancer control efforts throughout the cancer care continuum. The direct and indirect impacts of climate change on cancer risk, access to care, and outcomes are numerous and compounding, yet many oncology professionals might not be familiar with the strong connection between climate change and cancer. Thus, to increase awareness of this topic among cancer researchers, practitioners, and other professionals, this commentary discusses the links between climate change and cancer prevention and control, provides examples of adaptation and mitigation efforts, and describes opportunities and resources for future research.
Topics: Humans; Climate Change; Delivery of Health Care; Forecasting; Neoplasms
PubMed: 37184574
DOI: 10.1158/1055-9965.EPI-22-1234 -
Pathologie (Heidelberg, Germany) May 2024Due to the considerable technological progress in molecular and genetic diagnostics as well as increasing insights into the molecular pathogenesis of diseases, there has... (Review)
Review
Due to the considerable technological progress in molecular and genetic diagnostics as well as increasing insights into the molecular pathogenesis of diseases, there has been a fundamental paradigm shift in the past two decades from a "one-size-fits-all approach" to personalized, molecularly informed treatment strategies. Personalized medicine or precision medicine focuses on the genetic, physiological, molecular, and biochemical differences between individuals and considers their effects on the development, prevention, and treatment of diseases. As a pioneer of personalized medicine, the field of oncology is particularly noteworthy, where personalized diagnostics and treatment have led to lasting change in the treatment of cancer patients in recent years. In this article, the significant change towards personalized treatment concepts, especially in the field of personalized oncology, will be discussed and examined in more detail.
Topics: Precision Medicine; Humans; Neoplasms; Medical Oncology
PubMed: 38568256
DOI: 10.1007/s00292-024-01315-8 -
British Journal of Cancer Sep 2023Radiogenomics, focusing on the relationship between genomics and imaging phenotypes, has been widely applied to address tumour heterogeneity and predict immune... (Review)
Review
Radiogenomics, focusing on the relationship between genomics and imaging phenotypes, has been widely applied to address tumour heterogeneity and predict immune responsiveness and progression. It is an inevitable consequence of current trends in precision medicine, as radiogenomics costs less than traditional genetic sequencing and provides access to whole-tumour information rather than limited biopsy specimens. By providing voxel-by-voxel genetic information, radiogenomics can allow tailored therapy targeting a complete, heterogeneous tumour or set of tumours. In addition to quantifying lesion characteristics, radiogenomics can also be used to distinguish benign from malignant entities, as well as patient characteristics, to better stratify patients according to disease risk, thereby enabling more precise imaging and screening. Here, we have characterised the radiogenomic application in precision medicine using a multi-omic approach. we outline the main applications of radiogenomics in diagnosis, treatment planning and evaluations in the field of oncology with the aim of developing quantitative and personalised medicine. Finally, we discuss the challenges in the field of radiogenomics and the scope and clinical applicability of these methods.
Topics: Humans; Precision Medicine; Neoplasms; Medical Oncology; Genomics; Phenotype
PubMed: 37414827
DOI: 10.1038/s41416-023-02317-8 -
Revue Medicale de Liege May 2024Over the past 20 years, the number of new cancer diagnoses has risen steadily, partly due to the aging of the population. In 2021, 74,998 new diagnoses were recorded in... (Review)
Review
Over the past 20 years, the number of new cancer diagnoses has risen steadily, partly due to the aging of the population. In 2021, 74,998 new diagnoses were recorded in Belgium. At the same time, improved screening techniques and advances in oncology treatments have increased patient survival. As a result, the prevalence of cancer has risen: 4 out of every 100 Belgians are currently living with cancer. In addition to the symptoms caused by the disease, patients have to cope with the side effects of treatments. Quality of life is becoming essential in the care of these patients, and this requires better communication, quality information, and the implementation of appropriate preventive and therapeutic measures. Sexual health is an integral part of overall health, well-being, and quality of life. It must therefore be assessed and integrated into patient care throughout the entire course of treatment.
Topics: Humans; Sexual Health; Neoplasms; Quality of Life; Medical Oncology
PubMed: 38778650
DOI: No ID Found -
Cancer Dec 2023
Topics: Humans; Child; Surgical Oncology; Medical Oncology; Neoplasms
PubMed: 37897678
DOI: 10.1002/cncr.35073 -
The Veterinary Clinics of North... May 2024
Topics: Animals; Neoplasms; Veterinary Medicine
PubMed: 38105173
DOI: 10.1016/j.cvsm.2023.12.001 -
Pediatric Blood & Cancer Sep 2023The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid...
The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.
Topics: Child; Humans; Medical Oncology; Thyroid Neoplasms; Adrenal Cortex Neoplasms; Nasopharyngeal Neoplasms; Retinal Neoplasms
PubMed: 37458616
DOI: 10.1002/pbc.30574 -
Journal of Clinical Oncology : Official... Feb 2024Tumors of CNS are common in adolescents and young adults (AYAs). As the second leading cause of cancer-related death, CNS tumors in AYAs require improved clinical... (Review)
Review
Tumors of CNS are common in adolescents and young adults (AYAs). As the second leading cause of cancer-related death, CNS tumors in AYAs require improved clinical management. In this review, we discussed the current diagnostic approaches and recommended management strategies for malignant tumors in adult-type (IDH-mutant gliomas) and pediatric-type gliomas (pediatric high-grade gliomas), ependymoma and medulloblastoma, which commonly occur in AYAs. The impact of advanced molecular diagnostic approaches on the understanding of tumor biology of AYA CNS tumors is emphasized. To enhance participation in clinical trials, which poses a unique challenge in AYAs with CNS tumors, we propose encouraging referrals to neuro-oncology specialty care and improving collaboration between oncologists who care for both pediatric and adult patients. This will ensure better representation of AYA patients in research studies. Finally, we discussed the importance of considering neurocognitive and psychological function in AYAs with CNS tumor.
Topics: Humans; Adolescent; Young Adult; Child; Neoplasms; Central Nervous System Neoplasms; Glioma; Medulloblastoma; Ependymoma; Cerebellar Neoplasms
PubMed: 38064656
DOI: 10.1200/JCO.23.01747 -
JCO Precision Oncology May 2024
Topics: Humans; Neoplasms; Radiomics
PubMed: 38723232
DOI: 10.1200/PO.24.00155 -
Pediatric Blood & Cancer Sep 2023In the survivorship setting, adolescent and young adult (AYA) cancer survivors frequently demonstrate little knowledge of infertility risk, are unclear regarding their...
In the survivorship setting, adolescent and young adult (AYA) cancer survivors frequently demonstrate little knowledge of infertility risk, are unclear regarding their fertility status, and may under- or overestimate their treatment-related risk for infertility. In female AYA survivors, ovarian function usually parallels fertility, and can be assessed with serum hormone levels and ultrasonography. Posttreatment fertility preservation may be appropriate for survivors at risk for primary ovarian insufficiency. In male AYA survivors, fertility and gonadal function are not always equally affected, and can be assessed with a semen analysis and serum hormones, respectively. As reproductive health issues are commonly cited as an important concern by survivors of AYA cancer, multidisciplinary care teams including oncology, endocrinology, psychology, and reproductive medicine are advocated, with the aim of optimal provision of fertility advice and care for AYA cancer survivors.
Topics: Humans; Male; Female; Young Adult; Adolescent; Cancer Survivors; Fertility; Infertility; Survivors; Fertility Preservation; Neoplasms
PubMed: 37381152
DOI: 10.1002/pbc.28854